Jody Corey-Bloom

Jody Corey-Bloom

Auto-generated profile, based on publicly available information

Jody Corey-Bloom

Neurosciences UC San Diego San Diego California USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in NeuroImage
Verified
Journal Article
Closed access
VSVipul R Sheth
Vipul R Sheth
HSHongda Shao
Hongda Shao
JCJun Chen
Jun Chen
SVScott Vandenberg
Scott Vandenberg
JCJody Corey-Bloom
Jody Corey-Bloom
Jiang DuJiang Du
Jiang Du

11 August 2020 in Radiology
Verified
Journal Article
Closed access
YMYajun Ma
Yajun Ma
HJHyungseok Jang
Hyungseok Jang
ZWZhao Wei
Zhao Wei
ZCZhenyu Cai
Zhenyu Cai
YXYanping Xue
Yanping Xue
Jiang DuJiang Du
Jiang Du
A new three-dimensional short repetition time adiabatic inversion recovery–prepared ultrashort echo time sequence provided selective imaging of brain myelin with water signals efficiently suppresse... Background Water signal contamination is a major challenge for direct ultrashort echo time (UTE) imaging of myelin in vivo because water contributes most of the signals detected in white matter. Pu...

28 April 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
GPGeorgia M Parkin
Georgia M Parkin
JCJody Corey-Bloom
Jody Corey-Bloom
CSChase Snell
Chase Snell
JCJordan Castleton
Jordan Castleton
ETElizabeth A. Thomas
Elizabeth A. Thomas
To investigate whether plasma NfL levels correlate with clinical symptom severity in premanifest (PM) and manifest HD (HD) individuals, and whether a NfL cut-point could distinguish PM from HD patients with reasonable accuracy. 98 participants (33 control, 26 PM, 39 HD), underwent blood sample collection and clinical assessment, using both UHDRS and non-UHDRS measures, at one academic HD Center. Years to onset (YTO), probability of disease onset in 5 years, and predicted years until 60% onset probability were also calculated. NfL levels were measured using a Meso Scale Discovery assay. Cohorts differed by age. NfL levels differed significantly across diagnostic groups and were significantly correlated with age. Age-adjusted NfL levels were not correlated with clinical measures in either HD or PM cohorts, but were correlated when cohorts were combined. In PM subjects, NfL levels correlated with YTO, probability of onset in 5 years, and years until 60% onset probability. Using ROC analysis, a NfL cut-point of <53.15 pg/ml distinguished HD from control; <74.84 pg/ml distinguished HD from PM. These findings implicate plasma NfL as a peripheral prognostic marker for premanifest-HD. Notably, we show that significant correlations between NfL and clinical symptoms are detected only when PM + HD subjects are combined, but not within HD subjects alone. To date, prior studies have investigated the clinical usefulness of NfL exclusively in merged PM + HD cohorts. Our data suggests a biasing of these previous correlations, and hence potentially limited usefulness of plasma NfL in monitoring HD symptom progression, for example, in clinical trials.

Verified
Journal Article
Open access
PDF file
JCJody Corey-Bloom
Jody Corey-Bloom
RFRyan S. Fischer
Ryan S. Fischer
AKAeri Kim
Aeri Kim
CSChase Snell
Chase Snell
GPGeorgia M Parkin
Georgia M Parkin
ETElizabeth A. Thomas
Elizabeth A. Thomas
Growing evidence suggests that inflammatory responses, in both the brain and peripheral tissues, contribute to disease pathology in Huntington’s disease (HD), an inherited, progressive neurodegenerative disorder typically affecting adults in their 30–40 s. Hence, studies of inflammation-related markers in peripheral fluids might be useful to better characterize disease features. In this study, we measured levels of C-reactive protein (CRP), Interleukin-6 (IL-6), interleukin 1 beta (IL-1B), and alpha-amylase (AA) in saliva and plasma from n = 125 subjects, including n = 37 manifest HD patients, n = 36 premanifest patients, and n = 52 healthy controls, using immunoassays. We found increases in salivary levels of IL-6, IL-1B and CRP across different disease groups and increased levels of IL-6 in the plasma of HD patients as compared to premanifest patients and controls. The levels of salivary IL-6 were significantly correlated with each of the other salivary markers, as well as with IL-6 levels measured in plasma. Further, salivary IL-6 and IL-1B levels were significantly positively correlated with Total Motor Score (TMS) and chorea scores and negatively correlated with Total Functional Capacity (TFC) in HD patients, whereby in healthy control subjects, IL-6 was significantly negatively correlated with Montreal Cognitive Assessment (MoCA) and the Symbol Digit Modalities test (SDM). Interestingly, the plasma levels of IL-6 did not show similar correlations to any clinical measures in either HD or control subjects. These findings suggest that salivary IL-6 is particularly relevant as a potential non-invasive biomarker for HD symptoms. The advent of an effective, dependable salivary biomarker would meet the urgent need for a less invasive means of identifying and monitoring HD disease progression.

18 February 2021 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
HJH. Jang
H. Jang
YMY.-J. Ma
Y.-J. Ma
ECEric Chang
Eric Chang
SFS. Fazeli
S. Fazeli
RLRoland Robert Lee
Roland Robert Lee
Jiang DuJiang Du
Jiang Du
Circulating extracellular vesicles (EVs) present in the bodily fluids of patients with cancer may provide non-invasive access to the tumor tissue. Yet, the transcriptomic lineage of tumor-derived EVs before and after tumor-resection remains poorly understood. Here, we established 60 total small RNA-sequencing profiles from 17 aggressive prostate cancer (PCa) patient’s tumor and adjacent normal tissue, and EVs isolated from urine, serum, and cancer cell culture media. We interrogated the key satellite alteration in tumor-derived EVs and found that resection of tumor prostate tissue leads to differential expression of reactive oxygen species (ROS), P53 pathways, inflammatory/cytokines, oncogenes, and tumor suppressor genes in the EV nanosatellites. Furthermore, we provide a set of novel EV-specific RNA signature, which are present in cancer but are nonexistent in post-resection patients with undetectable cancer. Finally, using a de novo RNAseq assembly followed by characterization of the small RNA landscape, we found novel small RNA clusters (smRCs) in the EVs, which reside in the unannotated regions. Novel smRCs were orthogonally validated for their differential expression in the ‘biomarker discovery’ cohort using RT-qPCR. We demonstrate that circulating tumor EVs provide a glimpse of the tumor tissue biology, resolving a major bottleneck in the current liquid biopsy efforts. Secretory vesicles appear to be playing a key role in non-canonical Wnt signaling and miRNA pathways, similar to the circulating tumor cells (CTCs), hence, we propose that such vesicles be called circulating tumor extracellular vesicles (CTEVs).

1 January 2011 in Journal of Motor Behavior
Verified
Journal Article
Open access
TTTravis H Turner
Travis H Turner
JGJody Goldstein
Jody Goldstein
JHJoanne M. Hamilton
Joanne M. Hamilton
MJMark Jacobson
Mark Jacobson
EPEva Pirogovsky
Eva Pirogovsky
JCJody Corey-Bloom
Jody Corey-Bloom
Initiation and inhibition of saccadic eye movements has been shown to be impaired in patients with Huntington's disease (HD) and premanifest gene carriers (PMGC), and may provide biomarkers useful in tracking phenotypic change. Computerized behavioral tests of prosaccade latency and disinhibition presented to 31 non–gene carriers (NGC), 25 PMGC, and 12 HD patients. These tests provided quantitative performance measures without use of eye-tracking equipment. Significant differences on saccade tests were found, with PMGC intermediate between NGC and HD patients. Saccade latency discriminated PMGC from NGC, whereas saccade disinhibition discriminated PMGC from HD patients. Results suggest utility of behavioral saccade measures as premanifest indicators of phenoconversion in HD.